Abivax (AAVXF) Cash from Discontinued Operations (2024 - 2026)

Abivax has reported Cash from Discontinued Operations for 3 years, with the latest figure at -$53.3 million in Q1 2026.

• On a quarterly basis, Cash from Discontinued Operations fell 19.87% year-over-year to -$53.3 million in Q1 2026; TTM through Mar 2026 was -$357.8 billion, a N/A change from a year earlier, with the FY2025 full-year figure at -$191.8 billion, down 15.44% from the prior year.
• Cash from Discontinued Operations was -$53.3 million for Q1 2026 at Abivax, up from -$191.6 billion in the prior quarter.
• The five-year high for Cash from Discontinued Operations was -$44.5 million in Q1 2025, with the low at -$191.6 billion in Q4 2025.
• Average Cash from Discontinued Operations over 3 years is -$89.4 billion, with a median of -$83.0 billion recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Cash from Discontinued Operations declined 15.42% in 2025, then retreated 19.87% in 2026.
• Over 3 years, Cash from Discontinued Operations stood at -$166.0 billion in 2024, then fell by 15.42% to -$191.6 billion in 2025, then soared by 99.97% to -$53.3 million in 2026.
• The last three Cash from Discontinued Operations figures came in at -$53.3 million (Q1 2026), -$191.6 billion (Q4 2025), and -$44.5 million (Q1 2025), per Business Quant data.